Johnson & Johnson (NYSE:JNJ) Shares Sold by Center For Asset Management LLC

Center For Asset Management LLC lowered its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 5.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,740 shares of the company’s stock after selling 98 shares during the period. Center For Asset Management LLC’s holdings in Johnson & Johnson were worth $273,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. DORCHESTER WEALTH MANAGEMENT Co grew its holdings in Johnson & Johnson by 0.6% during the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after purchasing an additional 414 shares in the last quarter. OneAscent Financial Services LLC grew its holdings in Johnson & Johnson by 82.8% during the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock valued at $1,542,000 after purchasing an additional 4,457 shares in the last quarter. TrueMark Investments LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at $1,458,000. RAM Investment Partners LLC grew its holdings in Johnson & Johnson by 4.5% during the 4th quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock valued at $265,000 after purchasing an additional 73 shares in the last quarter. Finally, RFG Advisory LLC grew its holdings in Johnson & Johnson by 12.6% during the 3rd quarter. RFG Advisory LLC now owns 18,758 shares of the company’s stock valued at $2,921,000 after purchasing an additional 2,102 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on JNJ. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 28th. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Raymond James raised their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Finally, Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.31.

Get Our Latest Analysis on JNJ

Johnson & Johnson Trading Down 2.2 %

Johnson & Johnson stock opened at $154.27 on Thursday. The firm’s 50-day moving average is $158.35 and its 200-day moving average is $156.49. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97. The company has a market cap of $371.76 billion, a P/E ratio of 11.17, a PEG ratio of 2.65 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same period last year, the firm posted $2.35 EPS. The company’s revenue for the quarter was down 9.7% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.